A Study to Investigate the Safety and Clinical Effect of Nexagon® as a Topical Treatment for Subjects With a Diabetic Foot Ulcer (DUNE)

Phase 2

Completed

• Conditions: Diabetic Foot Ulcers
• Interventions: Drug: Nexagon® vehicle; Drug: Nexagon® Low Dose; Drug: Nexagon® Medium Dose; Drug: Nexagon® High Dose

• Registration Number: NCT01490879
• Lead Sponsor: OcuNexus Therapeutics, Inc.

Brief Summary

This study is for Type I or Type II diabetic subjects with with a diabetic foot ulcer. The study is being done to determine if Nexagon® plus standard of care is more effective than placebo plus standard of care. Standard of care will include debridement of the ulcer, standardized dressings and standardized off-loading using a Removable Cast Walker.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2011-12-11
• Study First Submitted QC: 2011-12-11
• Study First Posted: 2011-12-13
• Study Start: 2012-07
• Primary Completion: 2014-02
• Status Verified: 2014-04
• Study Completion: 2014-04
• Last Update Submitted: 2014-04-29
• Last Update Posted: 2014-05-01

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 168

Inclusion Criteria

1. Diagnosis of diabetes mellitus (Type I or II)
2. HbA1c of less than or equal to 12.0%
3. Diagnosis of neuropathic foot ulcer with partial or complete neuropathy
4. Cutaneous ulcer on the plantar or dorsal aspect of the foot or toe that is greater or equal to 1.0cm2 and less than or equal to 8.0 cm2 in area at the end of the screening period and is full thickness with no exposed ligament, tendon, joint capsule or bone. Surface area will be measured by digital planimetry.
5. The Medical Monitor(or delegate)must confirm that the reference diabetic foot ulcer (RDFU)is suitable for inclusion after reviewing digital photographs
6. Wound bed consisting of completely viable tissue or one where completely viable tissue will be achieved by the end of the screening period.
7. An Ankle Branchial Index (ABI) of greater or equal to 0.80 in concert with a bi- or tri-phasic Doppler flow pattern; or adequate circulation as demonstrated by any of the following methods: peri-wound transcutaneous partial pressure oxygen (TcpO2)greater or equal to 40 mmHg; or a toe pressure of greater or equal to 40 mmHg; or skin perfusion pressure of greater or equal to 40 mmHg.
8. Ulcer present for 4 weeks or more or less than or equal to 12 months.
9. Willing to wear a Removable Cast Walker (RCW) between study visits for the duration of the study.
10. Signed informed consent form.

Exclusion Criteria

1. Any unstable medical condition that would cause the study to be detrimental to the subject.

2. Decrease in RDFU size by more than 40% or increase in the ulcer size by more than 40% during the 14-day screening period as measured by digital planimetry.

3. Ulcers caused primarily by untreated vascular insufficiency or ulcers with an etiology not related to diabetes.4. Ulcers above the ankle.

4. Ulcers that cannot be effectively off-loaded using the cast walker and sole insert provided in this study (ulcers not located on the weight bearing surface of the foot do not require off-loading).

5. Ulcers on the toes not accessible for photography (e.g. in the web space). 7. Presence of other ulcers within 2cm of the perimeter of the RDFU. 8. BMI > 45 9. Cannot tolerate or will not comply with the off-loading method, or non-compliance with standard or care.

10.The RDFU is infected (clinical assessment of infection)and/or biopsy proof of greater than 100,000 organisms per gram of tissue during the screening period.

11. Subjects presenting with the clinical characteristics of cellulitis at the ulcer site. 12. Necrosis, purulence, or sinus tracts that cannot be removed by debridement.13. Definite or suspected osteomyelitis within any wound located anywhere on the subjects body.14. Acute Charcot's neuroarthropathy as determined by clinical and/or previous radiographic examination.

12. Severe Charcot deformity or rocker bottom foot with an associated plantar mid-foot or heel ulcer.

13. Revascularization surgery on the leg with the wound to be treated less than or equal to 4 weeks prior to the start of the screening period.

14. Requirement for concurrent topical antimicrobials to treat the RDFU after the end of the screening period.

15. Received dermal substitute or living skin equivalent (e.g. Dermagraft® or Apligraf®) within 14 days prior of the start of the screening period.

16. Severe complications of diabetes that in the opinion of the Investigator could interfere with wound healing or impede the subject's participation.

17. Subjects on concurrent immunosuppressive therapy to include oral corticosteroid therapy equivalent to greater than 5 mg/day of prednisone.

18. Any history of radiation therapy to the foot. 22. Female subjects who are pregnant or lactating. 23. Pre-menopausal women not using effective birth control methods as determined by the Investigator. 24. Life expectancy of < 12 months. 25. Subjects on renal replacement therapy. 26. Cancer within the last 3 years except basal and squamous cell carcinoma. 27. Cancer within the RDFU

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Nexagon® vehicle	Nexagon® vehicle	Twice weekly applications of Nexagon® vehicle in addition to off-loading using a Removable Cast Walker
Nexagon® Low Dose	Nexagon® Low Dose	Twice weekly applications of Nexagon® low dose in addition to off-loading using a Removable Cast Walker
Nexagon® Medium Dose	Nexagon® Medium Dose	Twice weekly applications of Nexagon® medium dose in addition to off-loading using a Removable Cast Walker
Nexagon® High Dose	Nexagon® High Dose	Twice weekly applications of Nexagon® high dose in addition to off-loading using a Removable Cast Walker

Primary Outcome Measures

Name	Time	Method
Incidence of Reference Diabetic Foot Ulcer (RDFU) complete closure determined by Investigator Assessment	Within 12 weeks

Secondary Outcome Measures

Name	Time	Method
Percentage of granulation tissue in RDFU	12 weeks
Percentage change in RDFU surface area	Within 12 weeks
Time to RDFU complete closure	Within 12 weeks
Incidence of ulcer recurrence	12 weeks post-closure
Incidence of adverse events	12 weeks

Trial Locations

Locations (25)

Advanced Foot Care and Clinical Research Center; 🇺🇸 Fresno, California, United States

Doctors Research Network; 🇺🇸 South Miami, Florida, United States

Advanced Foot and Ankle Center; 🇺🇸 Las Vegas, Nevada, United States

University of Arizona Medical Center; 🇺🇸 Tucson, Arizona, United States

Endocrinology Science Center; 🇷🇺 Moscow, Russian Federation

St Petersburg Diagnostic Center; 🇷🇺 St Petersburg, Russian Federation

Moscow Medical University n.a.; 🇷🇺 Moscow, Russian Federation

Federal bureau of medical and social expertise, Moscow; 🇷🇺 Moscow, Russian Federation

Ivano-Frankivsk Central City Clinical Hospital; 🇺🇦 Ivano-Frankivsk, Ukraine

Kyiv City Clinical Hospital #1; 🇺🇦 Kyiv, Ukraine

Institute of Endocrinology and Methabolism n.a. V.P. Komisarenko, Clinical Diabetology Department; 🇺🇦 Kyiv, Ukraine

Voronezh Regional Clinical Consultative Diagnostic Center; 🇷🇺 Voronezh, Russian Federation

St Petersburg City Hospital of St Elizabeth; 🇷🇺 St Petersburg, Russian Federation

Kemerovo Regional Clinical Hospital; 🇷🇺 Kemerovo, Russian Federation

Cherkasy Regional Clinical Hospital, Endocrinology Department; 🇺🇦 Cherkasy, Ukraine

City Clinical Hospital #13; 🇷🇺 Moscow, Russian Federation

Dnipropetrovsk Regional Clinical Hospitaln. a. I.I. Mechnikov; 🇺🇦 Dnipropetrovsk, Ukraine

Regional Clinical Hospital, Cardiovascular Surgery Department; 🇺🇦 Kharkiv, Ukraine

Zaporizhzhya City Clinical Hospital #9; 🇺🇦 Zaporizhzhya, Ukraine

Associated Foot and Ankle Specialists, LLC; 🇺🇸 Phoenix, Arizona, United States

Barry University Clinical Research; 🇺🇸 Hialeah, Florida, United States

Univeristy of Miami, Miller School of Medicine, Dermatology Research; 🇺🇸 Miami, Florida, United States

Houston Foot and Ankle Care; 🇺🇸 Houston, Texas, United States

Endocrinology Clinic of Moscow, Department of Healthcare; 🇷🇺 Moscow, Russian Federation

Center For Clinical Research Inc.; 🇺🇸 Castro Valley, California, United States